Literature DB >> 10583018

Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination.

N G Grubb1, D W Rudy, D C Brater, S D Hall.   

Abstract

AIMS: To assess if futile cycling of ketoprofen occurs in patients with decreased renal function.
METHODS: Ketoprofen was administered to six haemodialysis-dependent patients with end-stage renal disease as single (50 mg) or multiple doses (50 mg three times daily, for 7 days). Plasma and dialysate concentrations of the unconjugated and glucuronidated R- and S-enantiomers of ketoprofen were determined using h.p.l.c. following the single and multiple dosing.
RESULTS: The oral clearance was decreased and terminal elimination half-lives of R- and S-ketoprofen and the corresponding acyl glucuronides were increased in functionally anephric patients compared with healthy subjects. In contrast with the R-isomers, S-ketoprofen and S-ketoprofen glucuronide exhibited an unexpected accumulation (2.7-3. 8 fold) after repeated dosing achieving S:R ratios of 3.3+/-1.7 and 11.2+/-5.3, respectively. The plasma dialysis clearances for R- and S-ketoprofen glucuronides were 49.4+/-19.8 and 39.0+/-15.9 ml min-1, respectively, and 10.8+/-17.6 and 13.3+/-23.5 ml min-1 for unconjugated R- and S-ketoprofen.
CONCLUSIONS: The selective accumulation of S-ketoprofen and its acyl glucuronide are consistent with amplification of chiral inversion subsequent to futile cycling between R-ketoprofen and R-ketoprofen glucuronide. Severe renal insufficiency, and possibly more modest decrements, results in a disproportionate increase in systemic exposure to the S-enantiomer which inhibits both pathologic and homeostatic prostaglandin synthesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583018      PMCID: PMC2014373          DOI: 10.1046/j.1365-2125.1999.00046.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  42 in total

Review 1.  Glucuronidation and disposition of drug glucuronides in patients with renal failure. A review.

Authors:  R K Verbeeck
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

2.  Pharmacokinetics of ketoprofen in the elderly.

Authors:  C Advenier; A Roux; C Gobert; P Massias; O Varoquaux; B Flouvat
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

3.  Pharmacokinetics of naproxen in subjects with normal and impaired renal function.

Authors:  M Anttila; M Haataja; A Kasanen
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

4.  Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine.

Authors:  R A Upton; J N Buskin; R L Williams; N H Holford; S Riegelman
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

5.  Reduced glomerular function in rheumatoid arthritis.

Authors:  H C Burry
Journal:  Ann Rheum Dis       Date:  1972-01       Impact factor: 19.103

6.  Pharmacokinetics of ketoprofen enantiomers in cholecystectomy patients: influence of probenecid.

Authors:  R T Foster; F Jamali; A S Russell
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Benoxaprofen kinetics in renal impairment.

Authors:  G R Aronoff; T Ozawa; K A DeSante; J F Nash; A S Ridolfo
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

8.  Pharmacokinetics of ketoprofen in patients with chronic renal failure.

Authors:  G Stafanger; H W Larsen; H Hansen
Journal:  Scand J Rheumatol       Date:  1981       Impact factor: 3.641

9.  Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle.

Authors:  P J Meffin; D M Zilm; J R Veenendaal
Journal:  J Pharmacol Exp Ther       Date:  1983-12       Impact factor: 4.030

10.  Effects of probenecid on ketoprofen kinetics.

Authors:  R A Upton; R L Williams; J N Buskin; R M Jones
Journal:  Clin Pharmacol Ther       Date:  1982-06       Impact factor: 6.875

View more
  10 in total

Review 1.  Measurement of renal function during drug development.

Authors:  D Craig Brater
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 2.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

3.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of dexketoprofen.

Authors:  M J Barbanoj; R M Antonijoan; I Gich
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Stereoselective binding of mexiletine and ketoprofen enantiomers with human serum albumin domains.

Authors:  Da Shi; Yin-xiu Jin; Yi-hong Tang; Hai-hong Hu; Si-yun Xu; Lu-shan Yu; Hui-di Jiang; Su Zeng
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

6.  Stereoselective Pharmacokinetics of Ketoprofen After Oral Administration of Modified-Release Formulations in Caucasian Healthy Subjects.

Authors:  Marianela Lorier; Laura Magallanes; Manuel Ibarra; Natalia Guevara; Marta Vázquez; Pietro Fagiolino
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

7.  Different compositions of pharmaceuticals in Dutch and Belgian rivers explained by consumption patterns and treatment efficiency.

Authors:  Thomas L ter Laak; Pascal J F Kooij; Harry Tolkamp; Jan Hofman
Journal:  Environ Sci Pollut Res Int       Date:  2014-06-29       Impact factor: 4.223

Review 8.  Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

Authors:  Roger K Verbeeck; Flora T Musuamba
Journal:  Eur J Clin Pharmacol       Date:  2009-06-20       Impact factor: 2.953

Review 9.  Assessing and Treating Chronic Pain in Patients with End-Stage Renal Disease.

Authors:  Flaminia Coluzzi
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

10.  Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.

Authors:  Melanie S Joy; Reginald F Frye; Kristi Stubbert; Kim R Brouwer; Ronald J Falk; Evan D Kharasch
Journal:  J Clin Pharmacol       Date:  2010-01-26       Impact factor: 3.126

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.